The Biotech Pulse S1E1 - The manufacturing of complex biologics

Originally published here.

Keywords
contract manufacturer, manufacturing, product, gene therapy, immunotherapy, philip, biotech, process, work, virus, development, launch, house, pivotal, point, establish, biologics, study, capacity, pulse

The first episode of The Biotech Pulse concentrates on the Manufacturing of Complex Biologics. Forbion General Partner Rogier Rooswinkel speaks to Replimune CEO Philip Astley-Sparke. 

Philip Astley-Sparke is not only the company's Chief Executive Officer, but he is also its co-founder, and has served as a member of the Replimune board since its formation in 2015. Philip was previously the President and CEO of BioVex Inc that developed the first oncolytic therapy which was approved in the U.S. and Europe in 2015. Biovex was acquired by Amgen for up to $1bn in 2011. Tune in to listen to Philip's insight about Contract Development and Manufacturing Organizations (CDMOs) and when to recognize if it is the right time to go it alone.

Forbion is a leading life sciences venture capital firm founded in the Netherlands, helping companies bridge research and development through our team's expertise in drug development and company building. For over 15 years, we have invested in over 100 companies backing exciting therapies that we believe have the potential to impact the future of medicine. The Biotech Pulse is a forum where we speak about all things biotech with diverse stakeholders in the life sciences industry.